Company / Shareholders' Equity
Amgen Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$8.7B
FY2025
5-year range
$3.7B / $8.7B
FY2021-FY2025
Trend
+47.3%
vs FY2024
Sector context
#13 of 215
Health Care
What the data says
Among 215 Health Care companies, Amgen is in the top 6% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from $3.7B in FY2022 to $29.9B in FY2016.
Based on SEC 10-K filings.
$8.7B in FY2025 with a 5-year CAGR of -1.6%. Top quartile in the Health Care sector.
Improved from $6.2B to $8.7B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +33.2%
- 5-Year CAGR
- -1.6%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 215This company $8.7B Sector average $2.6B
▼
+238.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -1.6%, indicating a declining trend.
- In FY2025, shareholders' equity increased 47.3% year-over-year.
- Ranks #13 out of 215 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.7B | +47.3% |
| FY2024 | $5.9B | -5.7% |
| FY2023 | $6.2B | +70.2% |
| FY2022 | $3.7B | -45.4% |
| FY2021 | $6.7B | -28.8% |
| FY2020 | $9.4B | -2.7% |
| FY2019 | $9.7B | -22.6% |
| FY2018 | $12.5B | -50.5% |
| FY2017 | $25.2B | -15.5% |
| FY2016 | $29.9B | +6.4% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026